Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated

By the mid-1980s MDMA had become widely used recreationally and was also reported, in anecdotal clinical settings, to produce striking therapeutic breakthroughs when given adjunctively in psychotherapy. At an Esalen conference the author encountered experienced therapists who described rapid retrieval of traumatic memories and sudden improvements in long-standing treatment stalemates following MDMA administration. Those reports, together with the prospect of imminent emergency scheduling of MDMA by the DEA as a ‘‘hallucinogenic amphetamine,’’ motivated an effort to examine whether MDMA’s pharmacology and structure were in fact distinct from classical psychedelic phenethylamines. This paper sets out to articulate the rationale for a new pharmacological class — entactogens — centred on MDMA and related compounds. Rather than presenting a systematic review, the article traces the structural, stereochemical, preclinical and early clinical evidence that informed the entactogen concept, and summarises later studies that validated key mechanistic and behavioural features relevant to therapy and social effects.

This is a narrative, historically oriented review that draws on the author’s own experimental work together with selected preclinical and clinical studies from the 1970s onward. The text does not report a systematic literature search or formal inclusion criteria; instead, it highlights representative experiments and findings that were pivotal in distinguishing MDMA-like drugs from classical psychedelics and from psychostimulants. Evidence presented includes stereochemical syntheses and comparisons of enantiomers performed by the author’s group, in vitro assays using prelabeled brain synaptosomes to measure neurotransmitter release and uptake inhibition, animal two-lever drug discrimination paradigms, and referenced human pharmacological challenge studies that used receptor or transporter antagonists/pretreatments (for example, SSRIs, ketanserin, haloperidol). Where available, the review also integrates selected clinical observations and later mechanistic animal studies that examined brain-region and receptor-specific contributions to prosocial effects.

Stereochemical and structural comparisons established several distinctions between MDMA and classic phenethylamine psychedelics. MDMA’s active enantiomer is S-(+), whereas many hallucinogenic phenethylamines are more active as the R enantiomer; this reversal of stereochemistry suggests different mechanisms of action. MDMA also contains an N‑methylated secondary amine and tolerates extension of the α‑methyl to an α‑ethyl group (as in MBDB) without loss of MDMA-like psychoactivity, features that are inconsistent with the structure–activity profile of classic hallucinogens. Animal drug discrimination studies showed that neither isomer of MDMA substituted in LSD-trained rats, nor did racemic MBDB or its enantiomers, whereas MBDB and MDMA substituted for each other in MDMA-trained animals, indicating shared subjective effects between MDMA and MBDB but not with classic serotonergic psychedelics. Shulgin’s uncontrolled human observations of racemic MBDB (150–200 mg orally) reported MDMA-like effects with slower onset and less stimulation; a small double-blind comparison found the S-(+)-MBDB enantiomer to be active at 125 mg. Preclinical pharmacology indicated that MDMA is a potent releaser of neuronal serotonin via carrier-mediated processes: release experiments in rat synaptosomes found rates of release at 1.0 µM of 284 ± 16 (×10−4 min−1) for (+)-MDMA and 173 ± 6 for (−)-MDMA, showing greater activity of the S-(+) isomer. Binding and uptake data identified highest affinity at serotonin uptake sites (for example, ~610 nM reported in one study), with substantially lower affinity at α2-adrenergic and 5-HT2 receptors. Comparative uptake inhibition work found MDMA and MBDB to be potent inhibitors of 5-HT uptake, whereas classic hallucinogens such as DOM lacked uptake inhibitory activity. Investigations of related compounds (for example, 3-methoxy-4-methylamphetamine, MMA) supported the transporter-mediated release hypothesis: MMA was a selective 5-HT uptake inhibitor (IC50 ≈138 nM racemate; 99 nM for the S‑enantiomer), substituted in MDMA-trained rats at similar potencies (reported 0.46 mg/kg for enantiomers), but unlike MDMA did not produce the repeated-dose serotonergic deficits seen with high-dose MDMA. Other mechanistic studies (Rudnick & Wall; Nash et al.) demonstrated transporter-mediated serotonin release and minimal direct 5-HT2A agonism by (+)-MDMA, though some activity at 5-HT2C receptors was reported. More recent human pharmacological challenge studies validated the central role of serotonin release: pretreatment with SSRIs (citalopram, fluoxetine, paroxetine) attenuated many subjective effects of MDMA; duloxetine (a SERT/NET inhibitor) blocked MDMA-induced NE and 5-HT release in transfected cells and prevented acute psychoactive effects in humans. Behavioural experiments showed MDMA increases trust, generosity and empathy, and enhances social/emotional processing. A mouse study (Heifets et al.) demonstrated that MDMA’s prosocial effects require action at the serotonin transporter in the nucleus accumbens and involve 5-HT1B receptors, whereas MDMA’s psychostimulant/reward components are dopamine-dependent and separable from prosocial actions. Finally, clinical development led by MAPS culminated in a reported robust and durable therapeutic effect of MDMA-assisted therapy in a Phase 3 trial for PTSD.

Liechti and colleagues interpret these converging lines of evidence to support the entactogen classification as distinct from both classic psychedelic phenethylamines and from prototypical psychostimulants. Structural and stereochemical contrasts (reverse enantiomeric activity, N‑methylation tolerance, α‑ethyl permissiveness) argued early on that MDMA did not fit existing psychedelic structure–activity relationships. Functional pharmacology further separated entactogens by showing that transporter-mediated release of serotonin — resulting from uptake of the drug via SERT and reverse transport of 5‑HT — is a central mechanism, with norepinephrine release possibly contributing. Clinical pharmacological blockade studies (SSRIs, SERT/NET inhibitors) are cited as strong evidence that SERT-mediated serotonin release is necessary for most acute psychoactive effects of entactogens, though the authors acknowledge this may be necessary but not entirely sufficient to explain all pharmacodynamics. The authors position the prosocial and affiliative effects of MDMA as mediated by serotonergic signalling in the nucleus accumbens, specifically implicating 5-HT1B receptors, and contrast this with psychostimulant effects that rely on dopaminergic pathways. Limitations noted in the text include the narrative (non-systematic) nature of the review and remaining uncertainties about the contribution of norepinephrine to entactogen effects and whether SERT action alone fully accounts for the clinical profile. The authors also emphasise that later mechanistic and clinical advances — including rigorous human pharmacological studies and positive Phase 3 clinical results for MDMA-assisted therapy in PTSD — have validated many of the initial hypotheses that motivated the entactogen concept.

Structural, stereochemical and pharmacological evidence collectively distinguish entactogens from classic psychedelic phenethylamines and support recognising them as a separate class. A necessary component of entactogen action is carrier-mediated release of serotonin following drug uptake through SERT, with a potential contributory role for norepinephrine. Animal and human data implicate serotonin release and stimulation of 5-HT1B receptors in the nucleus accumbens as key to MDMA’s prosocial effects. Conceptually, entactogens can be viewed as the serotonergic counterparts of psychostimulants, where carrier-mediated monoamine release underlies their primary pharmacology.